Execution - Golimumabum, solution for injection - NFZ Drug Program
This tender has been awarded
Awarded to Janssen-Cilag Polska Sp. z o.o.; Abbvie sp. zo.o.; Farmacol Logistyka Sp. z o. o.; Lek S.A.; Urtica Sp. z o.o. — €59,808,005
About This Opportunity
TranslatedThis tender concerns the procurement of Golimumab, a solution for injection, as part of the National Health Fund (NFZ) Drug Program. The contracting authority requires that the offered medicinal product must possess all necessary attestations, certificates, and registrations in accordance with applicable legal regulations. Specifically, the product must comply with the provisions of the Act of April 12, 2024, Pharmaceutical Law (Uniform Text, Journal of Laws of 2024, item 686) and meet the prevailing norms or technical specifications for such a product. The contracting authority permits the submission of equivalent products, provided they offer chemical, physical, and quality parameters no less favorable than those specified in the Statement of Requirements (SWZ). This allowance for equivalents specifically applies to products where the contracting authority has indicated trademarks, patents, or origin. Furthermore, the contracting authority allows for the offering of pharmaceutically and therapeutically equivalent products that are also reimbursed by the National Health Fund. Pharmaceutical equivalence is defined as containing the same amount of active substance in the same dosage form, meeting comparable standards, and intended for the same route of administration. Therapeutic equivalence, however, requires both pharmaceutical equivalence and demonstrated comparable efficacy and safety profiles in equivalent doses, based on appropriate studies. Detailed requirements for the subject of the contract are outlined in Annex No. 2b to the SWZ. Contractors offering products must adhere to these specifications.
This is a supplies contract in the health and medical services sector, with a focus on Pharmaceuticals. Located in Poland, Europe, this opportunity is open to firms and consortiums.
Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.
Description
Auto-translated from Polish3.3. Contracting Authority's requirements regarding the subject of the order: 1) the offered medicinal product must have approvals, certificates and be registered in accordance with the provisions of law requiring approvals, certificates and registration, 2) the offered medicinal product must be placed on the market in accordance with the requirements of the Act of April 12, 2024, Pharmaceutical Law, consolidated text (Journal of Laws of 2024, item 686), 3) the offered medicinal product must comply with the standards or technical specifications applicable to this product; 3.4. The Contracting Authority allows the possibility of using equivalent products, i.e. with chemical, physical and quality parameters not worse than those specified in the SWZ – exclusively in relation to products whose origin has been specified by the Contracting Authority by indicating trademarks, patents or origin. The Contracting Authority allows the possibility of offering equivalent products specified in the SWZ, i.e. pharmaceutically and therapeutically equivalent and reimbursed by the National Health Fund. Pharmaceutical equivalence defines the situation where compared drugs contain the same amount of active substance in the same dosage form, corresponding to the same comparable standards and intended for administration by the same route; pharmaceutical equivalence does not guarantee therapeutic equivalence, as differences in excipients and the manufacturing process may cause differences in dissolution and bioavailability, and consequently in the effect of the pharmaceutical substance. Therapeutic equivalence - two substances are therapeutically equivalent if they are pharmaceutically equivalent and if, after their administration in the same dose, their effects in terms of both efficacy and safety are as could be expected based on appropriate studies. The Contracting Authority's requirements regarding the subject of the order have been specified in Annex No. 2b to the SWZ. If the Contractor applying for the order offers, by indicating in the price form, a subject of the order equivalent to that specified in the SWZ, they are obliged - in order to confirm that the offered supplies meet the Contracting Authority's requirements specified in the SWZ - to describe each of the equivalent solutions in the price form (Trade name, international name, number of units in the package of the offered product). The Contracting Authority agrees to a change in the dosage form of oral preparations, i.e. pricing: -instead of tablets – coated tablets, ampoules – vials; -instead of coated tablets – tablets, capsules or dragees -instead of capsules – coated tablets, tablets, or dragees Instead of tablets, coated tablets, or slow-release capsules – tablets, coated tablets, or capsules, and modified-release and vice versa. An equivalent solution means a solution that allows achieving the effect intended by the Contracting Authority and specified in the SWZ using other solutions. The Contractor offering solutions equivalent to those described by the Contracting Authority is obliged to define and describe the equivalent solutions, filling in the price form accordingly, the template of which is an annex to the SWZ. 3.5. The Contracting Authority requires the execution of the subject of the order on the terms specified in the agreement. The draft provisions of the public procurement agreement, which will be introduced into the agreement, constitute annexes to the SWZ. INFORMATION ON INTENDED ORDERS REFERRED TO IN ART. 214(1)(7) AND (8), IF THE CONTRACTING AUTHORITY INTENDS TO AWARD SUCH ORDERS The Contracting Authority does not intend to award orders referred to in art. 214(1)(7) of the Pzp Act. The Contracting Authority does not intend to award orders referred to in art. 214(1)(8) of the Pzp Act. DESCRIPTION OF THE CRITERIA THE CONTRACTING AUTHORITY WILL USE TO SELECT THE OFFER, INCLUDING THE WEIGHTS OF THESE CRITERIA AND THE METHOD OF EVALUATING OFFERS 13.1. The evaluation of offers will be carried out based on the criteria specified in the SWZ and their weights. Offers will be evaluated on a point basis. During the evaluation of offers...
Data provenance
This notice is sourced from TED - Tenders Electronic Daily (EU) and was originally published on March 12, 2025. Last refreshed 45 days ago. Original language: Polish. BidsFactory mirrors official procurement notices and links back to the source for full legal text.
About Górnośląskie Centrum Medyczne im. prof. Leszka Gieca Śląskiego Uniwersytetu Medycznego w Katowicach
Górnośląskie Centrum Medyczne im. prof. Leszka Gieca Śląskiego Uniwersytetu Medycznego w Katowicach has issued 585 procurement notices on BidsFactory, including 7 currently open and 411 awarded contracts. Activity concentrates in Health & Medical, General Supplies & Services, and Information & Communication Technology. All notices are published for Poland. Notices are distributed via TED - Tenders Electronic Daily (EU) and Poland e-Zamówienia. Most recent publication: September 23, 2026.
Frequently asked questions about this tender
How can I submit a bid?
Visit TED - Tenders Electronic Daily (EU) to access the full notice, required documents, and submission instructions provided by the contracting authority.
Is this tender still open?
No — the contract has already been awarded to Janssen-Cilag Polska Sp. z o.o.; Abbvie sp. zo.o.; Farmacol Logistyka Sp. z o. o.; Lek S.A.; Urtica Sp. z o.o.. The award notice is archived on BidsFactory for transparency and market intelligence.
Who is the contracting authority?
This notice was issued by Górnośląskie Centrum Medyczne im. prof. Leszka Gieca Śląskiego Uniwersytetu Medycznego w Katowicach in Poland. The authority is responsible for evaluating bids, awarding the contract, and managing performance.
What type of contract is this?
This is a Supplies contract in the Health & Medical sector. The classification helps bidders match the opportunity to their qualifications and registered scope of supply.
How much was the contract awarded for?
Janssen-Cilag Polska Sp. z o.o.; Abbvie sp. zo.o.; Farmacol Logistyka Sp. z o. o.; Lek S.A.; Urtica Sp. z o.o. was awarded the contract for €59,808,005. The figure reflects the value disclosed by the contracting authority in the award notice.
Where will the contract be performed?
The contract is for delivery in Poland. Foreign bidders should review local registration, taxation, and any in-country presence requirements before submitting.
Find tenders like this automatically
Set up alerts and filters that match your business — never miss a relevant opportunity again.
Sectors & Categories
Contracting Authority
Companies That Won Similar
Companies with awards in Health & Medical in Poland